9459 Predicting and Addressing Relapse After HCT: MRD in AML Pretest

Predicting and Addressing Relapse After HCT: MRD in AML Pretest

1. Which of the following statements regarding measurable residual disease prior to allogeneic transplantation for AML is supported by existing evidence? *This question is required.

2. You should always wait for MRD negativity to refer a patient for HCT consultation. *This question is required.

3. Which variant below will be more stable for tracking MRD through treatment and subsequent relapse after HCT? *This question is required.